12 September 2019 - Eligible patients in Scotland will immediately have access to Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor) in combination with ivacaftor.

Vertex Pharmaceuticals today announced that eligible cystic fibrosis patients living in Scotland will now have access to Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor) in combination with ivacaftor following the signing of an access agreement.

As part of the 5-year agreement Vertex has also committed to collecting real world data on these medicines that will support any future submissions to the Scottish Medicines Consortium.

Read Vertex Pharmaceuticals press release